DevaCell is developing proprietary synthetic viral vector engineering technology, ONCoat, which solves key limitations of viral vector-based development of oncolytic virus therapy, gene therapy and vaccines:
- Protects highly immunogenic viruses from neutralization until vector reaches its targets
- Uniquely enables intravenous, systemic administration, with tissue-specific targeting
- Uniquely enables repeat administration
- Protects highly immunogenic viruses from neutralization until vector reaches its targets
- Uniquely enables intravenous, systemic administration, with tissue-specific targeting
- Uniquely enables repeat administration
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
DEVA-OV1
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
